GREENSTONE BIOSCIENCES, INC.
Palo Alto, CA · Founded 2021 · CIK 0001923859 · Biotech · Private
A kit of 100 ethnically diverse, sex-balanced human iPSC-derived cardiomyocyte lines for pharmacogenomics-based drug cardiotoxicity screening and patient stratification
greenstonebio.com →- Grants
- $2.7M
- 2 awards
- Sector median: 1
- Raised
- $10M
- 1 Form D · May 2022
- 53 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 12
- 0 granted · 12 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20212022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $10,200,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Ethnically Diverse iPSC-Cardiomyocyte Panel for Pharmacogenomics and Drug Safety Testing | $1,294,681 | |
| Federal grant | Department of Health and Human Services · Phase II · Ethnically Diverse iPSC-Cardiomyocyte Panel for Pharmacogenomics and Drug Safety Testing | $1,447,258 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2187 | NexImmune, Inc. | — | $35M |
| 2188 | Platform Therapeutics, Inc. | — | $1.8M |
| 2189 | Ceapro Inc. | — | $7.7M |
| 2190 | GREENSTONE BIOSCIENCES, INC. | — | $10M |
| 2191 | SILCSBIO LLC | — | — |
| 2192 | Hemab Therapeutics | — | — |
| 2193 | Medosome Biotec, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Jade ChaoExecutive Officer
Patents
- Genistein phosphate derivativesapplication
- Dihydroartemisinin derivatives and the treatment of fibrotic diseasesapplication
- Treatment of the adverse cardiovascular effects of cannabinoidsapplication
- Combination treatment of dilated cardiomyopathyapplication
- Treatment Of The Adverse Cardiovascular Effects Of Cannabinoidsapplication
- Combination Treatment Of Dilated Cardiomyopathyapplication
- Genistein Compositions for the Treatment of Cardiovascular Effects of Marijuanaapplication
- Genistein Phosphate Derivativesapplication
- Combination treatment of dilated cardiomyopathyapplication
- Dihydroartemisinin Derivatives And The Treatment Of Fibrotic Diseasesapplication
- Genistein phosphate derivativesapplication
- Dihydroartemisinin derivatives and the treatment of fibrotic diseasesapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.